Dáil Éireann Debate, Tuesday - 9 July 2013
540. Deputy Noel Coonan asked the Minister for Health the position regarding the inclusion of Pirfenidone in the GMS and community drug schemes; the current status of the application; the timeframe for decision; and if he will make a statement on the matter. [33369/13]
View answerThe HSE has completed the consideration of the pricing and reimbursement application for Pirfenidone (Esbriet). The pricing and reimbursement application and associated commercially confidential offer made by Intermune has been accepted. The HSE has been in contact with Intermune (the market authorisation holder) and has confirmed that it will be in a position to commence reimbursement from 1st of August 2013, subject to Intermune being in a position to launch the product. The HSE expects that Intermune will be in a position to launch on the 1st of August. The administrative processes to allow reimbursement to happen are ongoing and will be completed over the next few weeks.
